NatureMedic® Fucoidan + AHCC®: Pharmacist’s Evidence & Product Comparison Guide
CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist
Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience
What Is NatureMedic Fucoidan + AHCC®?
NatureMedic is a Japanese supplement brand that formulates products combining fucoidan from brown seaweed with AHCC® (Active Hexose Correlated Compound), a proprietary standardized cultured-mushroom-derived preparation developed in Japan. Both ingredients have been individually studied in peer-reviewed research. This article reviews what each ingredient is, what the human evidence shows, and how the product line compares — so you can make an informed decision with your pharmacist or physician.
What Is Fucoidan?
Fucoidan is a sulfated polysaccharide found in several brown seaweed species, including Cladosiphon okamuranus, Undaria pinnatifida, and Fucus vesiculosus. Fucoidan preparations have been investigated in human and preclinical research, including studies of immune-related biomarkers and selected oncology-adjacent applications. Importantly, fucoidan preparations can differ substantially by source species, molecular weight, extraction method, and composition, so findings from one preparation should not automatically be generalized to another. For a full overview, see our What Is Fucoidan? pharmacist guide →
What Is AHCC®?
AHCC® is a proprietary standardized cultured-mushroom-derived preparation developed in Japan. Its composition and manufacturing process distinguish it from generic mushroom extracts and other mushroom-derived supplements. Human studies have investigated AHCC® in several immune-related contexts, including immune biomarkers and persistent high-risk HPV infection. Research conducted on AHCC® should not be generalized to generic mushroom extracts or other mushroom-derived products that have not been manufactured to the same specification. For the full evidence review, see our AHCC® clinical evidence review →
What the Research Shows
- Fucoidan & NK cell activity: A double-blind, placebo-controlled pilot RCT (Tomori et al., 2021, PMID: 34203925) and a prospective open-label human study in male cancer survivors (Nagamine et al., 2020, PMID: 31814980) have investigated fucoidan’s effects on NK cell number and activity. NK activity did not significantly change in the total group in the Nagamine study; a significant increase was reported only in the male subgroup.
- Fucoidan & oncology support: An RCT by Tsai et al. (2017, PMID: 28430159) evaluated a specific low-molecular-weight fucoidan preparation as a supplemental therapy in metastatic colorectal cancer patients. Disease-control rate differed significantly between groups, but overall survival, progression-free survival, objective response rate, adverse effects, and quality of life did not significantly differ. This preparation is not the same as the NatureMedic combination product.
- AHCC® & HPV: Smith et al. (2022, PMID: 35814366) published a randomized, double-blind, placebo-controlled phase II study evaluating AHCC® supplementation in women with persistent high-risk HPV infection. This represents significant human evidence; it does not establish AHCC® as an approved treatment for HPV infection, and the AHCC® preparation studied is not equivalent to the NatureMedic combination product.
- AHCC® & immune markers: Terakawa et al. (2008, PMID: 18791928) conducted a double-blind, placebo-controlled RCT in 21 healthy volunteers. Dendritic-cell measures changed, but NK cell activity did not significantly differ between groups — an important null finding alongside the positive endpoints.
Important limitation: Both fucoidan and AHCC® have been independently studied using specific preparations under controlled research conditions. Human clinical evidence specifically evaluating the NatureMedic fucoidan + AHCC® combination product is not available. Ingredient-level research cannot be assumed to apply to a finished combination product.
Who Might Discuss This Formulation With Their Pharmacist?
- Adults interested in discussing fucoidan- and AHCC®-containing supplements with a pharmacist or healthcare professional.
- Individuals who understand that the clinical research discussed above primarily evaluates specific fucoidan preparations or AHCC® independently, rather than the finished NatureMedic combination.
- People seeking a combined fucoidan + AHCC® formulation for general nutritional supplementation rather than treatment of a diagnosed disease.
Patients with cancer, persistent HPV infection, autoimmune disease, or other significant medical conditions should discuss supplementation with their treating clinician. This product should not be used as a substitute for established medical treatment.
Pharmacist’s Note: As a PharmD, I discuss both fucoidan and AHCC® with patients considering evidence-based approaches to immune health, taking into account their individual medications, health conditions, and treatment goals. Patients on anticoagulants, immunosuppressants, or undergoing cancer treatment should consult a pharmacist or physician before starting either supplement. Call us at (408) 622-8068 for a free consultation.
Product Comparison
NatureMedic offers both capsule and liquid formats. The following comparison reflects currently listed product specifications. Consumers should verify current product labels for accurate ingredient quantities and certifications.
| Feature | Umi No Shizuku Capsule | NatureMedic 3-PLUS Capsule | NatureMedic AHCC® Capsule |
|---|---|---|---|
| Quantity | 120 capsules | 160 capsules | 160 capsules |
| Fucoidan Content | 212.5 mg/capsule | 250 mg/capsule | 162.5 mg/capsule |
| AHCC® | None | None | 75 mg/capsule |
| Certification | HFA Certified | cGMP | cGMP |
| Formulation Distinction | Fucoidan-only capsule formulation | Higher listed fucoidan content; multi-ingredient formulation | Combined fucoidan + AHCC® formulation |
| Feature | Umi No Shizuku Liquid | NatureMedic 3-PLUS Liquid | NatureMedic AHCC® Liquid |
|---|---|---|---|
| Fucoidan Content | 2,125 mg/bottle | 2,200 mg/packet | 1,300 mg/packet |
| AHCC® | None | None | 600 mg/packet |
| Certification | HFA Certified | cGMP | cGMP |
| Formulation Distinction | Fucoidan-only liquid formulation | Higher listed fucoidan content; multi-ingredient liquid formulation | Combined fucoidan + AHCC® liquid formulation |
Key References
Evidence note: These selected studies are summarized here for product-comparison context. Detailed study limitations, preparation-specific considerations, funding/material-provider disclosures, author affiliations, and broader evidence are maintained in Khang Pharmacy’s Fucoidan and AHCC® Clinical Evidence Libraries.
- HUMAN RCT Tomori M, Nagamine T, Miyamoto T, Iha M. Effects of Ingesting Fucoidan Derived from Cladosiphon okamuranus Tokida on Human NK Cells: A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Pilot Study. Mar Drugs. 2021;19(6):340. PMID: 34203925. DOI: 10.3390/md19060340.
- HUMAN RCT Tsai HL, Tai CJ, Huang CW, Chang FR, Wang JY. Efficacy of Low-Molecular-Weight Fucoidan as a Supplemental Therapy in Metastatic Colorectal Cancer Patients: A Double-Blind Randomized Controlled Trial. Mar Drugs. 2017;15(4):122. PMID: 28430159. DOI: 10.3390/md15040122. Note: disease-control rate differed significantly; OS, PFS, ORR, adverse effects, and QOL did not significantly differ.
- HUMAN RCT Smith JA, et al. AHCC® Supplementation to Support Immune Function to Clear Persistent Human Papillomavirus Infections. Front Oncol. 2022;12:881902. PMID: 35814366. DOI: 10.3389/fonc.2022.881902.
- HUMAN RCT Terakawa N, et al. Immunological effect of active hexose correlated compound (AHCC) in healthy volunteers: a double-blind, placebo-controlled trial. Nutr Cancer. 2008;60(5):643–651. PMID: 18791928. DOI: 10.1080/01635580801993280. Note: dendritic-cell measures changed; NK cell activity did not significantly differ between groups.
- HUMAN STUDY Nagamine T, Kadena K, Tomori M, Nakajima K, Iha M. Activation of NK cells in male cancer survivors by fucoidan extracted from Cladosiphon okamuranus. Mol Clin Oncol. 2020;12(1):81–88. PMID: 31814980. DOI: 10.3892/mco.2019.1943. Note: prospective open-label study, not randomized. Significant NK increase reported in male subgroup only; not significant in total group.
View the complete evidence libraries →
Peer-reviewed human studies on fucoidan and AHCC® — organized by health category with evidence labels and direct PubMed links.
FDA Disclaimer
*These statements have not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. The information provided is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
Reviewed by: Dai Tran, PharmD, MBA, B.S. View full bio →
CEO & Lead Pharmacist, Khang Pharmacy • CA/MN/TX Licensed Pharmacist
Clinical Insights Series • APhA Immunization Certified • 10+ Years Clinical Experience
Khang Pharmacy | 2451 S King Rd., Ste A1, San Jose, CA 95122 | (408) 622-8068 | www.khangpharmacy.com
